Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

XEN402 Relieves Pain in PHN Trial

By Drug Discovery Trends Editor | May 2, 2011

Xenon Pharmaceuticals Inc. announced that its novel ointment XEN402 demonstrated significant and clinically meaningful reductions in pain in patients with postherpetic neuralgia (PHN).

Xenon is developing XEN402 as a topical treatment for a variety of painful disorders including PHN, as it specifically targets sodium channels such as Nav1.7. Sodium channels are highly expressed in sensory nerve endings and can be up-regulated in chronic painful conditions. In this phase 2a crossover study, the first phase 2a study with this topical product, 56 patients were alternately treated for three weeks with XEN402 and placebo ointments. The proportion of patients reporting >30% and >50% (clinically meaningful) reductions in pain was significantly greater for XEN402 than for placebo (p=0.049 for >30% and p=0.008 for >50%). In this trial, XEN402 also showed favorable trends in other co-morbidities commonly associated with PHN, including improvements in sleep. Importantly, neither dizziness nor drowsiness was observed in the trial, potentially differentiating topical XEN402 from the currently available oral treatments for PHN.

“These positive data represent an important step forward in the development of topical XEN402 for the treatment of chronic pain,” said Xenon President & CEO, Dr. Simon Pimstone. “The medical need and the market potential for an effective and safe neuropathic pain treatment are considerable.  Over $4 billion per year is spent on such treatments, and despite this, many patients remain in considerable pain. Our PHN data showed XEN402 provides clinically meaningful responses by inhibiting those sodium channels involved in pain locally. These beneficial analgesic effects are even more encouraging given how well the product was tolerated.  We believe that these findings considerably enhance the market opportunity for this product.”

In Xenon’s two earlier pilot proof-of-concept studies dosing XEN402 orally, the compound was shown to provide relief from inflammatory dental pain and from the debilitating neuropathic pain associated with inherited erythromelalgia. Inherited erythromelalgia is caused by gain-of-function mutations in Nav1.7 and the XEN402 findings support its capacity to inhibit Nav1.7 mediated pain. These two earlier trials indicated that XEN402 can suppress both inflammatory and neuropathic pain, suggesting that topical XEN402 could have broad utilities for multiple painful conditions.

Dr. Paul Goldberg, Xenon’s VP, Clinical added, “This topical product may differentiate itself from other pain treatments in a number of ways.  It has an excellent safety profile and the potential to treat both neuropathic and inflammatory pain, and as an ointment, XEN402 may be applied to any anatomical region including the face or flexures. The product could be used both as a monotherapy, and given its negligible systemic exposures, as a safe adjuvant therapy to oral products.  We look forward to the ongoing development of this exciting novel product.”

Date: May 2, 2011
Source: Xenon Pharmaceuticals Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50